Pfizer warns of potential carcinogen in Viracept

Share this article:

Pfizer has issued a “Dear doctor” letter warning healthcare professionals of the presence of a potential carcinogen in Viracept and cautioning against its use in pregnant women and pediatric patients, FDA said.

Pfizer said pediatric and pregnant women patients should not be started on Viracept until further notice. While pregnant women should be switched to an alternate therapy, the company said, “FDA and Pfizer agree that the benefit-risk ratio remains favorable” for pediatric patients already on the drug.

The chemical, ethyl methanesulfonate (EMS), is a process-related impurity formed during manufacture of the drug that has been found to be teratogenic, mutagenic and carcinogenic in animals, though no data from human studies exists. The presence of EMS in heightened levels prompted Roche, which manufactures Viracept in Europe, to pull the drug from all EU markets in June. Pfizer said it tested all active ingredients and found levels substantially lower than those that prompted the Roche recall. The problem with the Roche drug was detected when the company received reports of tablets exuding a strange odor.

Separately, Pfizer chairman and CEO Jeff Kindler said yesterday at the Bear Stearns Healthcare Conference that the company expects Lipitor sales to be flat or down up to 5% on last year's numbers due to competition from generic Zocor (simvastatin). The company also announced it is closing its Sandwich, UK manufacturing plant and shedding 420 jobs as part of its ongoing cost-cutting efforts, though which it aims to cut 10% of its workforce by 2009.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...